en-academic.com

Eculizumab

Eculizumab

drugbox
type = mab

source = Humanized
target = Complement protein C5
CAS_number = 219685-50-4
ATC_prefix = L04
ATC_suffix = AA25
PubChem =
DrugBank =
chemical_formula =
molecular_weight = 148 kDa
bioavailability =
protein_bound =
metabolism =
elimination_half-life = 8 to 15 days (mean 11 days)
excretion =
pregnancy_AU =
pregnancy_US = C
pregnancy_category=
legal_AU =
legal_CA =
legal_UK = POM
legal_US = Rx-only
legal_status =
routes_of_administration = Intravenous infusion
licence_EU = Soliris
licence_US = Eculizumab

Eculizumab (INN and USAN, trade name Soliris) is a monoclonal antibody directed against the complement protein C5. This antibody blocks the cleavage of C5 and halts the process of complement-mediated cell destruction. Eculizumab is a product of Alexion Pharmaceuticals and has been shown to be effective in treating paroxysmal nocturnal hemoglobinuria. [cite journal | author = Hillmen P, Young N, Schubert J, Brodsky R, Socié G, Muus P, Röth A, Szer J, Elebute M, Nakamura R, Browne P, Risitano A, Hill A, Schrezenmeier H, Fu C, Maciejewski J, Rollins S, Mojcik C, Rother R, Luzzatto L | title = The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria | journal = N Engl J Med | volume = 355 | issue = 12 | pages = 1233–43 | year = 2006 | pmid = 16990386 | doi = 10.1056/NEJMoa061648] Eculizumab was approved by the United States Food and Drug Administration (FDA) on March 16, 2007 and was later approved by the European Medicines Agency on June 20, 2007.

Ecuilzumab exhibits its theraputic activity by binding to the 2b subunit of the C5 convertase enzyme. C5 convertase is produced by the binding of subunits C4b, C2a and C3b to the surface of the bacterium. Binding of Eculizumab to the 2b subunit results in a reduction of the esterase activity of this subunit, and therefore prevents C5 convertase from hydrolysizing C5 into the C5a and C5b subunits.

References

External links

* [http://www.healthvalue.net/globulerougeexplose.html Flash animation of eculizumab mechanism of action]

Wikimedia Foundation. 2010.

Look at other dictionaries:

  • Eculizumab — Masse/Länge Primärstruktur 148 kDa …   Deutsch Wikipedia

  • Éculizumab — L éculizumab (nom commercial Soliris) est un anticorps monoclonal dirigé contre la fraction C5 du complément. En se liant avec le facteur C5, il en bloque son clivage (empêche la formation de C5a et C5b) et inhibe de ce fait, en partie, le… …   Wikipédia en Français

  • eculizumab — A monoclonal antibody used to prevent red blood cells from being destroyed in patients with paroxysmal nocturnal hemoglobinuria (PNH), a red blood cell disorder. Monoclonal antibodies are made in the laboratory and can locate and bind to… …   English dictionary of cancer terms

  • eculizumab — noun A monoclonal antibody directed against the complement protein C5 …   Wiktionary

  • eculizumab — ecu·liz·u·mab (ĕ ku lizґoo mab) a recombinant monoclonal antibody that binds to the terminal human complement protein C5 to prevent its cleavage; administered orally in treatment of paroxysmal nocturnal hemoglobinuria …   Medical dictionary

  • Soliris — Eculizumab Größe 148 kDa Bezeichner Externe IDs CAS Num …   Deutsch Wikipedia

  • Hämolytisch-urämisches Syndrom — Klassifikation nach ICD 10 D59.3 Hämolytisch urämisches Syndrom …   Deutsch Wikipedia

  • Enterohämorrhagische Escherichia coli — Klassifikation nach ICD 10 A04 Sonstige bakterielle Darminfektionen A04.3 Darminfektion durch enterohämorrhagische Escherichia coli …   Deutsch Wikipedia

  • Paroxysmale nokturne Hämoglobinurie — Bei der paroxysmalen nächtlichen Hämoglobinurie (PNH) handelt es sich um eine seltene erworbene Erkrankung blutbildender Stammzellen. Ursache ist eine Genmutation, welche die Funktion gewisser Proteine auf den Blutzellen stört. Kardinalsymptome… …   Deutsch Wikipedia

  • Paroxysmal nocturnal hemoglobinuria — Classification and external resources ICD 10 D59.5 ICD 9 283.2 …   Wikipedia